KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) Return on Equity (2016 - 2025)

Rigel Pharmaceuticals has reported Return on Equity over the past 15 years, most recently at 0.01% for Q4 2025.

  • For Q4 2025, Return on Equity rose 5.0% year-over-year to 0.01%; the TTM value through Dec 2025 reached 0.01%, up 5.0%, while the annual FY2025 figure was 0.02%, 3.0% up from the prior year.
  • Return on Equity for Q4 2025 was 0.01% at Rigel Pharmaceuticals, up from 0.01% in the prior quarter.
  • Over five years, Return on Equity peaked at 0.07% in Q3 2022 and troughed at 0.54% in Q2 2022.
  • A 5-year average of 0.02% and a median of 0.01% in 2023 define the central range for Return on Equity.
  • Biggest five-year swings in Return on Equity: tumbled -54bps in 2022 and later skyrocketed 56bps in 2023.
  • Year by year, Return on Equity stood at 0.0% in 2021, then skyrocketed by 882bps to 0.04% in 2022, then crashed by -76bps to 0.01% in 2023, then plummeted by -471bps to 0.03% in 2024, then soared by 147bps to 0.01% in 2025.
  • Business Quant data shows Return on Equity for RIGL at 0.01% in Q4 2025, 0.01% in Q3 2025, and 0.02% in Q2 2025.